Full Press Release Details
Journal of Clinical MedicineCombining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models
GERN Positive Sentiment
September 22, 2026
Key Takeaway: The study published in the Journal of Clinical Medicine highlights the synergistic effects of combining the telomerase inhibitor Imetelstat with the BCL-2 inhibitor Venetoclax in treating Acute Myeloid Leukemia (AML). The results from both cellular and animal models indicate that this combination enhances apoptosis and improves survival rates, suggesting a promising therapeutic strategy for AML patients.
Price reaction · baseline $1.31 (2026-09-22 close) · hit after-hours · clean, no other GERN news in the window
day 0 close · peak
-5.3%
day 1
-3.8%
day 3
-4.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Imetelstat combined with Venetoclax shows enhanced apoptosis.
- Improved survival rates observed in models.
- Potential for significant advancements in AML treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+185%
120-day peak, hindsight
Typical move
12%
average across 5 past catalysts
Cash runway
~60 mo
Minimal dilution risk
Lead asset
Imetelstat
Phase 3 · Myelofibrosis
Frequently Asked Questions
What is the focus of the study published in the Journal of Clinical Medicine?
The study focuses on the combination of Imetelstat and Venetoclax in treating Acute Myeloid Leukemia.
How does the combination of Imetelstat and Venetoclax affect AML?
The combination enhances apoptosis and improves survival rates in AML cellular and animal models.
What type of models were used in the study?
Both cellular and animal models were utilized to assess the treatment effects.
What are Imetelstat and Venetoclax used for?
Imetelstat is a telomerase inhibitor, while Venetoclax is a BCL-2 inhibitor, both targeting cancer cells.